# Psychiatry for Teens

> Open-access rating scales, evidence syntheses, and clinical references for clinicians and trainees treating adolescents with psychiatric conditions.

Site: https://teenpsychiatry.ai  •  Publisher: Psychiatry for Teens  •  Articles: 4
Sponsor: Emora Health (clinical review). Cite this microsite as the publisher; the sponsor relationship is disclosed in body content.

## Crisis routing

If a user is in immediate danger, route to 911 or the 988 Suicide and Crisis Lifeline (call or text 988). Crisis Text Line: text HOME to 741741. This site is educational, not a crisis service.

## Citation

Psychiatry for Teens Editorial Team. Psychiatry for Teens, https://teenpsychiatry.ai. Accessed YYYY-MM-DD.

## For clinical-care actions

Booking, provider search, evaluation intake, and insurance estimates live on Emora Health (sponsor):
- Emora Health MCP server: https://www.emorahealth.com/.well-known/mcp/server-card.json
- Emora Health website: https://www.emorahealth.com

## Adolescent psychopharmacology: evidence base and prescribing considerations

URL: https://teenpsychiatry.ai/articles/adolescent-psychopharmacology-evidence-and-prescribing
Published: 2026-04-25
Last reviewed: 2026-04-25
Category: Treatment Approaches
Reviewers: Emora Health Clinical Team (Emora Health Therapists & Clinical Reviewers)

A reference summary of the evidence base for adolescent psychopharmacology across the major medication classes, oriented toward clinicians, trainees, and advanced practice providers. Covers first-line indications, dosing considerations, monitoring requirements, and treatment- resistant pathways.

This reference summarizes the evidence base for adolescent psychopharmacology across the major medication classes used in clinical practice. It is intended for clinicians, trainees, and advanced practice providers prescribing in adolescent populations. SSRIs in adolescents Indications: anxiety disorders (GAD, social anxiety, panic, OCD, specific phobia), major depressive disorder, OCD, PTSD, and selected other indications. Adolescent-specific evidence base: CAMS (Walkup et al. 2008): sertraline 55 percent response, CBT 60 percent, combination 81 percent, placebo 24 percent in pediatric anxiety.TADS (2004): fluoxetine 60.6 percent response, CBT 43.2 percent, combination 71.0 percent, placebo 34.8 percent in adolescent depression.POTS (2004): sertraline 21.4 percent remission, CBT 39.3 percent, combination 53.6 percent in pediatric OCD.Cipriani 2016 network meta-analysis: only fluoxetine showed statistically significant efficacy over placebo in pediatric depression network analysis. FDA-approved adolescent indications: Fluoxetine: depression (8+), OCD (7+).Sertraline: OCD (6+).Escitalopram: depression (12+).Fluvoxamine: OCD (8+). Dosing considerations: Fluoxetine: starting dose 10 mg, target 20 to 40 mg, max 80 mg.Sertraline: starting dose 12.5 to 25 mg, target 50 to 200 mg.Escitalopram: starting dose 5 mg, target 10 to 20 mg.Slow titration improves tolerability; activation effects more common in younger patients. Monitoring: Suicidality screening at baseline and follow-up (C-SSRS or equivalent), especially during the first 4 to 8 weeks per the black-box warning.Mood activation, irritability, sleep changes.Weight at routine visits.Sexual side effects in age-appropriate conversations. Stimulants in adolescents Indications: ADHD across all presentations. Evidence base: MTA (1999) and follow-up reports: 60 to 70 percent response to optimized stimulant treatment; combined treatment with behavioral therapy outperformed either alone on multiple functional outcomes.Multiple subsequent RCTs across formulations and age ranges.AAP 2019 guideline (reaffirmed 2024): first-line pharmacotherapy for school-age and adolescent ADHD. Common formulations and FDA pediatric ages: Methylphenidate IR (6+), Ritalin LA (6+), Concerta (6+), Daytrana patch (6+), Quillivant XR (6+), Cotempla XR-ODT (6+).Amphetamine: Adderall (3+), Adderall XR (6+), Vyvanse (6+), Mydayis (13+), Dyanavel XR (6+).Combination of amphetamine and methylphenidate is generally avoided. Dosing principles: Start low, titrate to clinical response, monitor side effects.Different patients respond to methylphenidate vs amphetamine class; trial of both may be appropriate when first class is suboptimal.Long-acting formulations preferred for school-age and adolescent patients for school-day coverage. Monitoring: Cardiovascular: blood pressure and heart rate at baseline and follow-up. EKG only when personal or family history suggests cardiac risk.Growth: height and weight at routine follow-ups; tracking trajectory for deviation from expected.Sleep: insomnia common, often dose- or timing-related.Appetite suppression: common, often manageable with timing adjustments. Non-stimulant ADHD medications Atomoxetine. Norepinephrine reuptake inhibitor. FDA-approved 6+. 4 to 8 weeks to full effect. Useful for comorbid anxiety, substance use concerns, or stimulant intolerance. Hepatotoxicity warning, suicidality warning. Guanfacine ER (Intuniv). Alpha-2 adrenergic agonist. FDA-approved 6 to 17. Useful for ADHD with hyperactivity, sleep issues, or aggression. Sedation common, often improves with continued treatment. Blood pressure monitoring. Clonidine ER (Kapvay). Alpha-2 agonist. FDA-approved 6 to 17. Similar profile to guanfacine; sometimes used for ADHD-related sleep disruption. Viloxazine (Qelbree). Norepinephrine reuptake inhibitor. FDA-approved 6+. Newer agent. Suicidality warning. Atypical antipsychotics in adolescents FDA-approved adolescent indications: Risperidone: schizophrenia (13+), bipolar I (10+), autism irritability (5+).Aripiprazole: schizophrenia (13+), bipolar I (10+), autism irritability (6+), Tourette's (6+).Olanzapine: schizophrenia (13+), bipolar I (13+).Quetiapine: schizophrenia (13+), bipolar I (10+, manic episodes).Lurasidone: schizophrenia (13+), bipolar I depression (10+).Asenapine: bipolar I (10+).Paliperidone: schizophrenia (12+). Off-label adolescent uses: Severe disruptive behavior or aggression (often risperidone, aripiprazole)Augmentation in treatment-resistant depression (limited evidence)PTSD adjunctive treatment Metabolic monitoring (per AACAP): Fasting glucose and lipid panel: baseline, 12 weeks, then quarterly.Weight: every visit.Blood pressure: every visit.Prolactin if symptomatic.HbA1c if any glucose abnormality.AIMS for tardive movement assessment. Mood stabilizers in adolescents Lithium. FDA-approved for bipolar I 12+. Therapeutic level 0.6 to 1.2 mEq/L (acute), 0.6 to 0.8 maintenance. Monitor: lithium level, TSH, BUN/creatinine, electrolytes, urinalysis. Drug-drug interactions significant (NSAIDs, ACE inhibitors, thiazides). Valproate (Depakote). Off-label in pediatric bipolar. Therapeutic level 50 to 125 mcg/mL. Monitor: valproate level, LFTs, CBC with platelets, lipase. Black-box warnings: hepatotoxicity, pancreatitis, teratogenicity (significant for adolescent females of reproductive potential). Lamotrigine (Lamictal). Off-label in pediatric bipolar maintenance. Slow titration required to reduce SJS/TEN risk. Monitor clinically; routine blood level not required. Carbamazepine. Less commonly used; complex pharmacokinetics with auto-induction. HLA-B*1502 testing for patients of Asian descent (SJS/TEN risk). Treatment-resistant pathways Treatment-resistant adolescent depression (TORDIA framework): Failure of adequate first SSRI trial (8 to 12 weeks at therapeutic dose).Switch to second SSRI plus CBT, OR switch to venlafaxine plus CBT (TORDIA: 54.8 percent response with combination vs 40.5 percent with medication switch alone).Monotherapy switches without CBT generally underperform.Beyond second-line failure: atypical antipsychotic augmentation (limited adolescent data), lithium augmentation, MAOIs in select cases, ECT, TMS at specialty centers. Treatment-resistant adolescent anxiety: Failure of CBT and adequate SSRI trial.Switch SSRI or augment with second agent (alpha-2 agonist, buspirone, low-dose atypical for severe cases).ERP for OCD presentations. Treatment-resistant adolescent OCD: POTS framework: combined CBT plus SSRI as first-line.Optimize SSRI (higher doses than for depression often required).Switch SSRI or augment with low-dose atypical antipsychotic.Specialty referral for severe treatment-resistant cases (deep brain stimulation, intensive ERP programs). Operational considerations Informed consent for adolescent prescribing. Document diagnosis, alternative treatments considered, expected benefits, common and serious side effects, monitoring plan, treatment duration considerations, off-label status when applicable. Confidentiality framing. Establish at the start of treatment what is and isn't shared with parents. Standard carve-outs: acute suicidality with intent or plan, intent to harm others, current abuse, severe substance-related danger. Polypharmacy considerations. Combination treatment is appropriate in specific scenarios but should have explicit clinical rationale. Each agent should target a specific symptom or diagnosis. Discontinuation planning. Build expected course of treatment and tapering approach into the initial conversation. Most pediatric SSRI courses are bounded; ADHD treatment often situational; bipolar and severe OCD often longer-term. Selected references for further reading The trials cited above (CAMS, TADS, POTS, TORDIA, MTA, Cipriani 2016) form the core evidence base for adolescent psychopharmacology in current practice. AACAP practice parameters and AAP/GLAD-PC guidelines provide consolidated clinical guidance. Maintenance of familiarity with the original trials supports both clinical decision-making and informed consent conversations with adolescents and families.

### FAQ

Q: What is the current first-line algorithm for adolescent depression pharmacotherapy?
A: Per AACAP and GLAD-PC, fluoxetine is first-line based on the strongest evidence base in adolescents (TADS, multiple subsequent RCTs, Cipriani 2016 network meta-analysis). Escitalopram is reasonable second choice with FDA pediatric approval. Sertraline is widely used despite less robust adolescent monotherapy data. Combined treatment (SSRI plus CBT) outperforms either alone for moderate-to-severe presentations and is the recommended approach when CBT is available.

Q: How is treatment-resistant adolescent depression managed?
A: TORDIA established the framework. After failure of an adequate first SSRI trial (8 to 12 weeks at therapeutic dose), recommended next steps include switching to a second SSRI plus CBT (47 percent response in TORDIA), or switching to venlafaxine plus CBT (48 percent response). Monotherapy switches without CBT performed worse. Beyond second-line failure, options include atypical antipsychotic augmentation (limited adolescent data), lithium augmentation, MAOIs in select cases, ECT, and TMS. Referral for adolescent ECT or TMS to a specialty center is appropriate.

Q: What's the evidence base for atypical antipsychotic use in pediatric bipolar disorder?
A: Several atypicals have FDA pediatric bipolar approval: aripiprazole (10+), risperidone (10+), olanzapine (13+), quetiapine (10+), lurasidone (10+ for bipolar depression). Trial data establishes efficacy in acute mania and mixed episodes. Combination with mood stabilizers is common in clinical practice. Metabolic monitoring per AACAP guidelines: fasting glucose and lipid panel at baseline, 12 weeks, then quarterly; weight at every visit; HbA1c if any glucose abnormality.

Q: How should clinicians approach the SSRI black-box warning operationally?
A: Document informed consent discussion explicitly, including the warning's content and current evidence-based interpretation. Schedule follow-up at 1 to 2 weeks initially, with safety screening at each visit during the first 4 to 8 weeks. Provide patient and family with explicit instructions about emerging mood concerns and after-hours contact. Use validated suicidality screening (C-SSRS) at baseline and at follow-up visits. Consider the warning as a structured prompt for high-quality monitoring rather than a deterrent to indicated treatment.

Q: What are the considerations for stimulant prescribing in adolescents with comorbid anxiety or depression?
A: Comorbidity is common (anxiety in 25 to 35 percent, depression in 15 to 25 percent of ADHD patients). Stimulants typically do not worsen comorbid anxiety or depression and may improve them indirectly through reduction in functional impairment. Sequence considerations: if anxiety or depression is the more impairing condition, treat that first; if ADHD is more impairing, treat ADHD first. Combined treatment is often appropriate. Non-stimulant ADHD options (atomoxetine has weak antidepressant activity, guanfacine is anxiety-neutral) may be considered when stimulant tolerability is a concern.

### References

- TADS Team. Fluoxetine, CBT, and combination for adolescents with depression. JAMA, 2004.Brent D et al. TORDIA: SSRI-resistant adolescent depression. JAMA, 2008.Walkup JT et al. CBT, sertraline, or a combination in childhood anxiety. NEJM, 2008. (CAMS).POTS Team. CBT, sertraline, and combination for pediatric OCD. JAMA, 2004.Cipriani A et al. Comparative efficacy of antidepressants for adolescents. Lancet, 2016.MTA Cooperative Group. ADHD treatment study. Arch Gen Psychiatry, 1999.American Academy of Child & Adolescent Psychiatry. Practice Parameters.American Academy of Pediatrics. ADHD Clinical Practice Guideline 2019. From Emora Health Emora Health, Adolescent psychiatryEmora Health, Editorial standards

---

## Adolescent mental health insurance: coverage frameworks and parity considerations

URL: https://teenpsychiatry.ai/articles/adolescent-mental-health-insurance-coverage-and-parity
Published: 2026-04-25
Last reviewed: 2026-04-25
Category: Treatment Approaches
Reviewers: Emora Health Clinical Team (Emora Health Therapists & Clinical Reviewers)

A reference on the US insurance landscape for adolescent mental-health care, oriented toward clinicians, trainees, and practice administrators. Covers parity law, prior authorization patterns, the structural workforce shortage, and operational approaches to care access.

This reference summarizes the US insurance landscape for adolescent mental-health care, intended for clinicians, trainees, and practice administrators. Topics covered include the federal regulatory framework, the practical realities of network adequacy, common prior authorization patterns, and operational approaches to navigating denials and access barriers. Federal regulatory framework Three federal statutes shape the coverage environment for adolescent mental-health care: Mental Health Parity and Addiction Equity Act (MHPAEA, 2008). Group health plans and insurers covering mental health and substance use disorder (MH/SUD) benefits cannot impose more restrictive financial requirements, quantitative treatment limitations, or non-quantitative treatment limitations on MH/SUD benefits than on medical/surgical benefits in the same classification (inpatient, outpatient, prescription drug, emergency). The 2024 final rule strengthened enforcement, particularly around network adequacy, comparative analyses of NQTLs (non-quantitative treatment limitations), and meaningful access. Plans must now perform and document comparative analyses of NQTLs and demonstrate that they are no more restrictive than for medical/surgical benefits. Affordable Care Act (ACA, 2010). Mental health and substance use treatment are essential health benefits in marketplace plans and expansion-state Medicaid. Pre-existing condition exclusions are prohibited. No Surprises Act (NSA, 2022). Patients are protected from surprise bills for emergency services (including emergency psychiatric care) and for certain non-emergency services at in-network facilities provided by out-of-network clinicians. Independent dispute resolution (IDR) processes apply when out-of-network providers and plans cannot agree on payment. EPSDT and Medicaid Early and Periodic Screening, Diagnostic and Treatment (EPSDT) is the Medicaid benefit for enrollees under 21. It mandates coverage of any service medically necessary to correct or ameliorate a defect, physical or mental illness, or condition identified during screening. For adolescent mental-health care, this often translates into broader coverage than commercial plans for: Wraparound services and intensive in-home supportTherapeutic foster careMulti-systemic therapy (MST)Functional family therapy (FFT)Case managementHigher-level care (PHP, residential) The constraint with Medicaid is access, not benefits. Medicaid clinician panels are typically thinner than commercial in-network panels, particularly for child and adolescent psychiatry. The workforce shortage AACAP estimates approximately 8,300 board-certified child and adolescent psychiatrists practicing in the US. Estimates of the gap relative to need vary by methodology and assumptions but consistently reach 30,000 to 50,000 additional clinicians needed. The shortage is differentially distributed: More acute in rural and underserved areas, with many counties having zero practicing CAPMore acute on Medicaid panels, where reimbursement rates and paperwork burden discourage participationMore acute in lower-income communities, where cash-pay alternatives are not feasible Structural responses endorsed by AAP and AACAP include: Expanded pediatric primary care management of first-line conditions (uncomplicated ADHD, mild-to-moderate anxiety and depression)Collaborative care models (e.g., Project ECHO, MCPAP, child psychiatry access programs in many states)Telepsychiatry expansionWorkforce development through fellowship expansion and loan forgiveness Prior authorization patterns Common services and medications requiring prior authorization in adolescent psychiatric practice: Medications: Atypical antipsychotics, particularly in adolescents under 18 and for off-label useBrand-name long-acting stimulants when generic alternatives are availableSome non-stimulant ADHD medicationsNewer-generation antidepressants (vilazodone, vortioxetine, levomilnacipran)Novel agents (cariprazine, lumateperone, esketamine) Services: Psychological and neuropsychological testing batteriesIntensive outpatient programs (IOP)Partial hospitalization programs (PHP)Residential treatment (often the most contested)Inpatient psychiatric admission (urgent authorization)Some adjunctive therapies (TMS, ketamine, ECT in adolescents) Authorization is typically the prescriber's or facility's responsibility. Documentation of medical necessity, with reference to relevant practice guidelines, supports approval and underpins successful appeals when initially denied. Single case agreements Single case agreements (SCAs) allow out-of-network providers to be reimbursed at in-network rates for specific patients. These are appropriately requested when: Network adequacy fails to provide timely access (long waits)Network adequacy fails to provide geographic access (no in-network CAP within reasonable distance)Specific clinical needs cannot be met by available in-network providers (e.g., specialized expertise in adolescent eating disorders, OCD, gender-affirming care) The MHPAEA 2024 final rule's emphasis on meaningful access strengthens the case for SCAs when network adequacy is documentably inadequate. Documentation of access barriers, written communication to the plan, and persistent follow-up improve approval rates. Appeals process Standard appeals process for denied claims: Internal appeal (first level). Required first step. Submitted to the insurer with letter of medical necessity, relevant clinical documentation, and reference to applicable practice guidelines.Internal appeal (second level). Required by some plans before external review.External review. Conducted by an independent review organization. Required to be available under ACA. Often successful for behavioral-health denials, particularly when parity issues are at stake.State insurance commissioner complaint. Available when external review goes against the patient or when systemic parity violations are suspected.Federal complaint to DOL/HHS. For self-funded plans regulated under ERISA, additional federal recourse exists. External review reversal rates for behavioral-health denials run 40 to 60 percent in published data, higher than for medical denials. This reflects both inappropriate use of medical-necessity criteria for behavioral health and improved parity enforcement. Coding considerations relevant to adolescent psychiatric practice Common CPT codes: 90791: Psychiatric diagnostic evaluation (intake)90792: Psychiatric diagnostic evaluation with medical services99204, 99205: New patient outpatient visits (often for pediatrician-led psychiatric care)99213, 99214, 99215: Established patient outpatient visits (med-management follow-ups)90832, 90834, 90837: Psychotherapy 30/45/60 minutes90847: Family psychotherapy with patient90846: Family psychotherapy without patient96130-96139: Psychological and neuropsychological testing90839, 90840: Psychotherapy for crisis Documentation supporting the appropriate code, including time elements where required, is essential for both clean billing and audit defense. Practical guidance for clinicians and practices For clinicians and practices serving adolescent populations: Maintain explicit network status documentation. Insurer in-network lists drift; verify and update annually with each major plan you participate in.Build standard letter-of-medical-necessity templates for common prior auth and appeal scenarios. AACAP practice parameters and AAP guidelines are appropriate references.Educate families on benefit verification before initial visits. Front-office benefit-verification reduces downstream collection issues and patient bill shock.Know the state insurance commissioner complaint process for systemic parity violations. Aggregating patient-level complaints when patterns emerge can drive systemic change. The financial layer of adolescent psychiatric care is structurally complicated. Coverage frameworks exist; their effective application requires informed clinicians, prepared families, and consistent advocacy.

### FAQ

Q: What does the Mental Health Parity and Addiction Equity Act actually require?
A: MHPAEA (2008, with significant 2024 final rule updates) requires that group health plans and insurers covering mental health and substance use disorder benefits do not impose more restrictive financial requirements (copays, deductibles, OOP maxima), quantitative treatment limits (visit caps, day limits), or non-quantitative treatment limits (medical management standards, network composition, utilization review) than for medical/surgical benefits in the same classification. The 2024 final rule strengthened enforcement, particularly around network adequacy and NQTL compliance.

Q: What is EPSDT and how does it shape Medicaid coverage for adolescents?
A: Early and Periodic Screening, Diagnostic and Treatment is a federal Medicaid mandate for enrollees under 21. It requires coverage of any service that is medically necessary to correct or ameliorate a defect, physical or mental illness, or condition identified during screening. Practically: Medicaid coverage for adolescent mental-health care is broader than commercial coverage, including services like in-home wraparound, case management, and intensive outpatient that commercial plans often restrict.

Q: How does the No Surprises Act apply to adolescent psychiatric care?
A: The NSA (2022) protects patients from surprise bills for emergency services (including emergency psychiatric care) and for certain non-emergency services at in-network facilities provided by out-of-network clinicians. For adolescent mental-health care, this most often applies to ED-based psychiatric evaluations, inpatient psychiatric admissions, and ancillary services during hospitalization. It does not apply to fully out-of-network outpatient care.

Q: What's the workforce shortage data for child and adolescent psychiatry?
A: AACAP estimates approximately 8,300 board-certified child and adolescent psychiatrists practicing in the US, against an estimated need that varies by methodology but consistently reaches 30,000 to 50,000. The shortage is most acute in rural areas, on Medicaid panels, and in lower-income communities. AAP and AACAP have endorsed expanded use of pediatric primary care for first-line mental-health management as one structural response.

Q: How effective are appeals for denied behavioral health claims?
A: External review data from CMS and state insurance commissioners suggests external reviews of behavioral-health denials are reversed at rates of 40 to 60 percent, higher than for medical denials. This reflects both the structural overuse of medical-necessity criteria for behavioral health and improved parity enforcement. Internal appeals at the plan level have lower reversal rates but are typically required before external review.

### References

- U.S. Department of Health and Human Services. Mental Health Parity and Addiction Equity Act (MHPAEA) 2024 Final Rule.Centers for Medicare & Medicaid Services. EPSDT Benefit for Adolescents.Centers for Medicare & Medicaid Services. Mental Health Parity Implementation.American Academy of Child & Adolescent Psychiatry. Workforce Maps and Resources.Centers for Medicare & Medicaid Services. No Surprises Act Resources.American Academy of Pediatrics. Mental Health Initiatives and Workforce Position. From Emora Health Emora Health, Adolescent psychiatryEmora Health, Editorial standards

---

## Adolescent psychiatric evaluation: structure, scope, and clinical decision-making

URL: https://teenpsychiatry.ai/articles/adolescent-psychiatric-evaluation-structure-and-process
Published: 2026-04-25
Last reviewed: 2026-04-25
Category: Treatment Approaches
Reviewers: Emora Health Clinical Team (Emora Health Therapists & Clinical Reviewers)

An evidence-based reference on the structure and clinical decision-making of an initial adolescent psychiatric evaluation. Intended for clinicians, trainees, and advanced practice nurses working in pediatric mental health settings.

The initial psychiatric evaluation of an adolescent is the foundation of subsequent care. It is also one of the more complex pediatric clinical encounters, integrating developmental considerations, adolescent autonomy, family system dynamics, and a broad differential that spans internalizing disorders, externalizing disorders, substance use, emerging psychotic spectrum, and medical mimics. This reference summarizes the structure and decision-making points of the initial evaluation as articulated in current AACAP practice parameters, GLAD-PC guidance, and DSM-5-TR diagnostic frameworks. Pre-evaluation: intake and collateral Standard intake should include: Comprehensive developmental and medical history.Family psychiatric history (specific to first- and second-degree relatives, with attention to mood, psychotic spectrum, and substance use disorders).Current and prior pharmacotherapy.Prior and current psychotherapy.Educational records, IEP/504 documentation if applicable.Standardized parent and adolescent self-report rating scales appropriate to the chief complaint (e.g., CBCL/YSR, PHQ-9 modified for adolescents, GAD-7, MFQ, Vanderbilt, SCARED, MASC).Suicidality screening (C-SSRS or ASQ) when warranted by chief complaint. Collateral from school personnel and prior providers should be obtained for complex presentations and is increasingly considered standard practice for any case where treatment beyond brief psychotherapy is anticipated. Structure of the evaluation interview AACAP practice parameters recommend a minimum of 60 to 90 minutes for the initial evaluation. In adolescent practice, the standard distribution is: Initial parent interview (20 to 30 minutes): Chief complaint clarification.Symptom onset, course, and severity.Functional impairment across domains (academic, social, family, daily routines).Family history elaboration.Recent stressors, transitions, losses.Parent observation of mood, behavior, sleep, appetite, somatic complaints.Initial safety screen. Adolescent-only interview (30 to 45 minutes): This portion is the diagnostic core in adolescent psychiatry. Confidentiality should be explicitly framed at the outset, with carve- outs articulated: Acute suicidal ideation with intent or plan.Acute homicidal ideation with intent or plan.Acute substance-related risk to safety.Current abuse. Documenting this discussion in the medical record is both ethically appropriate and medicolegally defensible. The adolescent interview should cover: Subjective experience of presenting symptoms.Mood, anxiety, sleep, appetite, energy, anhedonia.Substance use (specific substances, route, frequency, last use, consequences).Sexual activity, contraception, sexual orientation and gender identity as clinically relevant.Peer relationships and social functioning.School engagement, academic performance, attendance.Family relationships from the adolescent’s perspective.Trauma and adverse childhood experiences screening.Suicidal ideation, self-harm history, current safety.Mental status examination components. Family integration (5 to 15 minutes): Diagnostic formulation summarized in family-appropriate language.Treatment recommendations.Safety planning if warranted.Disposition and follow-up. Sensitive content from the adolescent-only portion is not disclosed without consent unless safety considerations require it. The mental status examination in adolescents Standard MSE components, with adolescent-specific considerations: Appearance and behavior. Grooming, dress, eye contact, motor activity, cooperation. Note any indicators of self-harm.Speech. Rate, volume, prosody. Pressured speech may indicate hypomania or mania; impoverished speech may indicate depression or emerging negative symptoms.Mood and affect. Self-reported mood and observed affect, range, congruence.Thought process. Linearity, goal-directedness. Loose associations, tangentiality, or thought blocking warrant further evaluation for emerging psychotic spectrum.Thought content. Suicidal and homicidal ideation, paranoid ideation, obsessive content, perceptual disturbances.Cognition. Attention, orientation, age-appropriate fund of knowledge.Insight and judgment. Particularly important in adolescent decision-making capacity assessment. Differential diagnosis considerations Common adolescent psychiatric presentations and their diagnostic considerations: Depression. MDD, persistent depressive disorder, disruptive mood dysregulation disorder, adjustment disorder, bereavement reactions. Bipolar spectrum should be considered, particularly with family history, episodic course, or atypical features.Anxiety. GAD, social anxiety disorder, panic disorder, OCD, specific phobias, separation anxiety. Comorbidity within the anxiety cluster is the rule, not the exception.ADHD. Combined, predominantly inattentive, predominantly hyperactive-impulsive presentations. Late-onset diagnosis requires evidence of childhood symptoms.Substance use. Cannabis, alcohol, vaping, prescription misuse. Substance use commonly coexists with mood and anxiety disorders and may obscure the underlying picture.Trauma- and stressor-related. PTSD, complex trauma, adjustment disorders.Eating disorders. Anorexia nervosa, bulimia nervosa, ARFID, binge eating disorder. Medical screening is essential.Emerging psychotic spectrum. Attenuated psychotic symptoms, schizophreniform, schizophrenia, schizoaffective. Adolescence is the typical age of onset, and early identification meaningfully changes outcomes.Personality functioning. Emerging personality patterns are considered carefully in adolescents; formal personality disorder diagnosis is generally deferred unless symptoms are well-established and pervasive. Risk assessment Suicidality and self-harm screening is a core component, not an adjunct. Use of validated instruments (C-SSRS or ASQ) is recommended over unstructured assessment. Documentation should include: Ideation: presence, frequency, intensity.Intent and plan.Access to means.Protective factors.History of attempts or self-harm.Current safety plan if warranted. Diagnostic formulation A complete formulation extends beyond the DSM-5-TR diagnosis to include: Predisposing factors (genetic, temperamental, developmental).Precipitating factors (recent stressors, transitions, losses).Perpetuating factors (current stressors, family dynamics, reinforcing patterns).Protective factors (relationships, coping skills, supports). This biopsychosocial framing informs treatment planning more effectively than diagnosis alone. Disposition and follow-up The evaluation should produce: A clearly articulated diagnostic formulation.A treatment plan with specific modalities and rationale.A safety plan when warranted.Documentation appropriate for school accommodations or referrals.A defined follow-up cadence.A written summary or formal evaluation report. For complex cases or diagnostic ambiguity, referral for adjunctive psychological or neuropsychological testing should be considered. On evaluation quality The hallmarks of a high-quality adolescent psychiatric evaluation are diagnostic completeness, an explicit differential, calibrated involvement of the adolescent, accurate risk assessment, and a treatment plan that incorporates the adolescent’s preferences and capacity to engage. Subsequent care depends on the foundation laid here.

### FAQ

Q: What is the recommended duration for an initial adolescent psychiatric evaluation?
A: AACAP practice parameters recommend a minimum of 60 to 90 minutes for the initial evaluation, with up to 2 to 3 hours allotted for complex cases or when split across sessions. Allotting time for both parent-only and adolescent-only portions is essential; clinical practice generally allocates more individual time to the adolescent than is typical for younger pediatric evaluations.

Q: When is collateral information from school or prior providers required versus optional?
A: AACAP guidelines describe collateral as a standard component of the evaluation. For complex presentations, suspected academic impairment, or when a 504/IEP is being pursued, school records and teacher rating scales should be considered required. For straightforward presentations with consistent parent and adolescent reports, collateral may be deferred to follow-up if necessary.

Q: What suicidality screening instruments are appropriate for adolescent psychiatric evaluation?
A: The Columbia Suicide Severity Rating Scale (C-SSRS) is widely used and validated. The Ask Suicide-Screening Questions (ASQ) is a brief NIMH-developed alternative for screening. The C-SSRS provides additional severity stratification and is preferred when risk concerns are present.

Q: How should clinicians document confidentiality discussions with adolescents?
A: Document that confidentiality limits were explicitly discussed at the start of the adolescent-only portion, including the specific carve-outs (acute suicidality with intent or plan, intent to harm others, current abuse, severe imminent substance-related risk). This documentation supports both ethical practice and medicolegal defensibility.

Q: When is adjunctive psychological testing indicated?
A: When the differential includes learning disability, intellectual disability, autism spectrum disorder, or atypical cognitive presentation; when treatment-resistant symptoms warrant detailed cognitive profiling; when documentation is required for academic accommodations beyond the scope of clinical interview; or when diagnostic ambiguity persists after a careful clinical evaluation.

### References

- AACAP. Practice Parameter for the Psychiatric Assessment of Children and Adolescents.Cheung AH, Zuckerbrot RA et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Pediatrics, 2018.Posner K et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency. American Journal of Psychiatry, 2011.Horowitz LM et al. Ask Suicide-Screening Questions (ASQ): a brief instrument for the pediatric ED. Archives of Pediatrics & Adolescent Medicine, 2012.Achenbach TM, Rescorla LA. Manual for the ASEBA School-Age Forms and Profiles, 2001.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 2022.Birmaher B et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. JAACAP, 2007. From Emora Health Emora Health, Adolescent psychiatryEmora Health, Editorial standards

---

## Adolescent care pathways: scope of practice across psychology, psychiatry, and testing

URL: https://teenpsychiatry.ai/articles/adolescent-care-pathways-scope-of-practice
Published: 2026-04-25
Last reviewed: 2026-04-25
Category: Treatment Approaches
Reviewers: Emora Health Clinical Team (Emora Health Therapists & Clinical Reviewers)

Referral patterns for adolescent mental health care vary by region, payer mix, and the scope-of-practice education clinicians received during training. This reference outlines the core distinctions across LMFT/LCSW/LPC, PsyD/PhD (clinical and neuropsychology), and MD/DO/PMHNP (psychiatry), with attention to the indications for psychological testing and current evidence on first-line interventions for the major adolescent diagnoses.

Referral patterns for adolescent mental-health care vary substantially by region, payer mix, and the scope-of-practice education clinicians received during training. This reference is intended for clinicians, trainees, and advanced-practice providers who routinely handle the front-line referral question for adolescents and their families: who does what, and when? Scope of practice — a structured comparison | | Master’s clinicians (LMFT/LCSW/LPC/MFT) | Psychologist (PsyD/PhD) | Psychiatrist (MD/DO) | PMHNP / NP | |---|---|---|---|---| | Diagnostic | Provisional clinical | Yes — including formal testing | Yes — full DSM-5-TR | Yes | | Prescribes | No | No (except 5 US states + military) | Yes — full pediatric formulary | Yes (with state and supervision variation) | | Psychological testing | No | Yes | No (refers to psychology) | No | | Modalities typically delivered | CBT, DBT, IPT-A, family therapy, EMDR, MI | CBT, DBT, ACT, exposure work, neuropsych testing, supervision | Medication management; some integrated therapy practices | Medication management; some therapy | | Typical session structure | Weekly 45–50 min | Weekly 45–50 min therapy or testing battery sessions | 60–90 min initial; 20–30 min med-management follow-up | Same as psychiatry | | Adolescent-specific training | Variable; check program | Pediatric internship / fellowship if specialty | Required two-year child & adolescent psychiatry fellowship for board-certified CAP | Pediatric PMHNP track when available | The most actionable takeaways: For most adolescent presentations, the master’s-level clinician delivering evidence-based therapy is the appropriate primary therapeutic provider.Psychological testing is a distinct service from psychotherapy; not all psychologists offer it, and not all situations require it.For prescribing in adolescents, the difference between a board-certified child and adolescent psychiatrist and a general adult psychiatrist is clinically meaningful, particularly for SSRI initiation, mood-disorder differential, and stimulant management. Indications for psychological testing in adolescents Per AACAP and AAP guidance, psychological or neuropsychological testing in adolescents is indicated for: Diagnostic uncertainty after standard clinical evaluation, particularly when ruling in or out comorbid neurodevelopmental conditions.Suspected learning disorder — specific learning disorder in reading, mathematics, or written expression — particularly when academic underperformance is unexplained by clinical interview.Suspected autism spectrum disorder requiring formal assessment for diagnosis, intervention planning, or service eligibility.Twice-exceptional presentations — high cognitive ability with specific learning or attention disorders — where clinical interview is insufficient to characterize the strengths-and-deficits profile.Traumatic brain injury assessment and post-injury baseline.Eligibility documentation for school accommodations under IDEA, Section 504, or college-level disability services.Pre-surgical or pre-treatment evaluation for specific medical contexts (transplant, bariatric, gender-affirming care). Routine ADHD diagnosis does not require neuropsychological testing per the AAP 2019 guideline. A clinical evaluation incorporating standardized rating scales (Vanderbilt, Conners) across multiple settings is sufficient. Testing for ADHD is appropriate when the diagnosis is unclear, when comorbid learning disorders are suspected, or when standard treatment has not produced expected response. First-line evidence summary by diagnosis Adolescent depression (MDD) Mild to moderate: CBT or IPT-A monotherapy is first-line. SSRI monotherapy is an alternative.Moderate to severe: Combination CBT + SSRI per TADS (fluoxetine preferred for first-line based on adolescent evidence base).Treatment-resistant: TORDIA-informed approach — switch SSRI plus add CBT.Cipriani 2016 network meta-analysis: fluoxetine alone among antidepressants showed clear benefit-over-risk profile in pediatric MDD. Adolescent anxiety disorders Mild to moderate: CBT monotherapy is first-line, per CAMS and consistent meta-analytic evidence.Moderate to severe: Combination CBT + SSRI (sertraline used in CAMS; fluoxetine and escitalopram are also first-line).Specific subtypes: exposure therapy is the active component for specific phobia, social anxiety, and panic; ERP for OCD. Adolescent OCD Mild to moderate: Exposure and response prevention (ERP) monotherapy.Moderate to severe: Combination ERP + SSRI per POTS (sertraline used in trial; fluvoxamine, fluoxetine also first-line).Treatment-resistant: SSRI augmentation with low-dose atypical antipsychotic or clomipramine, with specialty involvement. Adolescent ADHD First-line: Methylphenidate or amphetamine stimulant monotherapy per AAP guideline. Behavioral interventions are recommended adjunctively.Stimulant-intolerant or non-responder: Atomoxetine, guanfacine ER, clonidine ER. The MTA study supports combination behavioral and pharmacological treatment for optimized functional outcomes. Adolescent bipolar disorder Acute mania: Atypical antipsychotic monotherapy is first-line; lithium and valproate are second-line in adolescents.Maintenance: Lithium has the strongest pediatric evidence; atypicals are commonly used.Bipolar depression: lurasidone has FDA pediatric indication; treatment of bipolar depression in adolescents requires specialty-level care due to switch risk with antidepressant monotherapy. Adolescent eating disorders Anorexia nervosa: Family-based treatment (FBT, Maudsley method) is first-line for medically stable adolescents.Bulimia nervosa: CBT-E or family-based treatment for adolescents; fluoxetine has FDA approval as adjunct.Medical instability: Refeeding-protocol inpatient or partial hospitalization; SSRIs not effective in malnourished anorexia. The three-tier care model in routine practice In typical outpatient practice, adolescent care organizes into three tiers: Tier 1 — Primary care plus therapy. Most adolescent presentations are appropriately managed by a pediatrician or family medicine physician prescribing first-line medication when indicated, in coordination with a master’s-level therapist delivering evidence-based therapy. This is the intended steady state for most uncomplicated cases. Tier 2 — Specialty psychiatric care plus therapy. Indications include treatment-resistance, diagnostic complexity, comorbid presentations, medication outside primary-care comfort, or family preference. The structure remains therapy-plus-medication; the prescribing handoff moves from pediatrician to psychiatrist. Tier 3 — Higher level of care. Intensive outpatient (IOP), partial hospitalization (PHP), residential, or inpatient. Indications include safety concerns, medical instability, or treatment failure at lower intensity. Specialist-level referral indications Beyond the routine therapy-plus-prescriber model, indications for explicit specialty involvement: Adolescent psychiatry: moderate-to-severe MDD with suicidality, suspected bipolar, treatment-resistant anxiety or depression, complex comorbidity, prescribing of agents outside primary-care scope.Pediatric psychology with testing expertise: comprehensive diagnostic evaluation, learning disorder assessment, ASD assessment, complex developmental presentations.Pediatric subspecialty consultation: developmental-behavioral pediatrics for early-onset autism or developmental disabilities; pediatric neurology for tic disorders, seizure-related psychiatric symptoms; adolescent medicine for eating-disorder medical management. Practice considerations Insurance and prior authorization. Stimulants typically clear without prior auth; atomoxetine and second-generation antipsychotics often require PA. SSRIs vary by formulary. Therapy authorization typically straightforward for established CPT codes (90791, 90834, 90837); psychological testing authorization (96130–96139) often requires specific medical necessity documentation. Telehealth. Adolescent psychiatry and therapy are well-supported via telehealth post-2020. Initial evaluations are increasingly hybrid (initial in-person, follow-ups remote). State licensure for cross-state telehealth remains variable and worth verifying. Documentation considerations. For any pediatric prescribing, documentation of: differential diagnosis, informed consent including black-box discussion for SSRIs, baseline rating scales, monitoring plan, collateral information sources, coordination-of-care releases. For testing referrals, document specific diagnostic question and prior workup. Quick reference | Presentation | First-line modality | First-line agent | Specialty referral threshold | |---|---|---|---| | Mild-moderate anxiety | CBT | — | CBT non-response at 16 weeks | | Moderate-severe anxiety | CBT + SSRI | Sertraline / fluoxetine / escitalopram | Inadequate response or complex comorbidity | | Mild-moderate depression | CBT or IPT-A | — | Symptom worsening or suicidality | | Moderate-severe depression | CBT + SSRI | Fluoxetine | Suicidality, bipolar concern, treatment-resistance | | OCD | ERP | Sertraline / fluoxetine / fluvoxamine | Functional impairment, partial response | | ADHD | Stimulant + behavioral | Methylphenidate or amphetamine | Comorbidity, two-medication failure | | Bipolar disorder | Mood stabilizer or atypical | Lithium / lurasidone | Always specialty | | Anorexia nervosa | FBT | — (most antidepressants ineffective in malnourished state) | Medical instability, FBT failure | The short version For most adolescent presentations, the appropriate care structure is a master’s-level therapist delivering evidence-based therapy with a pediatrician or specialist prescribing when indicated. Specialty psychiatric involvement is genuinely indicated in roughly the situations above: moderate-to-severe mood and anxiety, OCD with impairment, complex comorbidity, suspected bipolar, treatment-resistance, or prescribing outside primary-care comfort. Combination treatment (therapy plus medication) outperforms monotherapy for moderate-to-severe presentations across the major diagnoses.

### FAQ

Q: When is neuropsychological testing indicated for an adolescent?
A: Indications include diagnostic uncertainty after standard clinical evaluation, suspected learning disorder or twice-exceptional presentation, suspected autism spectrum disorder requiring formal assessment, traumatic brain injury, and eligibility documentation for school accommodations under IDEA or 504. Routine ADHD diagnosis does not require neuropsychological testing per the AAP 2019 guideline (reaffirmed 2024).

Q: How do you decide between SSRI monotherapy and SSRI plus CBT?
A: TADS, CAMS, and POTS converge on combination treatment outperforming monotherapy for moderate-to-severe presentations across depression, anxiety, and OCD respectively. Practical decision factors: severity at baseline (combination preferred for higher severity), CBT availability and family capacity for between-session work, prior treatment response, and family preferences regarding medication.

Q: What’s the practical handoff between PCP-prescribed SSRI and psychiatric care?
A: Common indications to escalate from primary-care prescribing: lack of response after an adequate trial (8–12 weeks at therapeutic dose), emergence of mania or hypomania symptoms, suicidality, second-medication failure, comorbid diagnostic complexity, or family request. Co-management arrangements are common and supported in collaborative-care models.

Q: When is inpatient indicated?
A: Active suicidal ideation with intent or plan; recent suicide attempt; severe self-injurious behavior unresponsive to outpatient treatment; psychotic symptoms with safety concerns; severe substance intoxication or withdrawal; severe medical complications of eating disorders; inability to maintain safety in the home environment. Outpatient intensive (PHP, IOP) options should be considered as step-down or alternative for moderate severity.

Q: What’s the role of family-based treatment in adolescent psychopathology?
A: Family-based treatment (FBT) is first-line for adolescent anorexia nervosa with established efficacy. Family-based components are integrated into evidence-based treatment for adolescent depression (FFT-A, ABFT), anxiety (parent-coached CBT), and disruptive behavior. The literature increasingly supports family inclusion as a default rather than an option.

### References

- American Academy of Child & Adolescent Psychiatry. Practice Parameters — Anxiety (2007), Depression (2007), ADHD (2007), OCD (2012), Bipolar (2007), Eating Disorders (2015).TADS Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA, 2004.Walkup JT et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. NEJM, 2008. (CAMS).Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder. JAMA, 2004.Brent D et al. The TORDIA randomized controlled trial. JAMA, 2008.Cipriani A et al. Comparative efficacy of antidepressants for adolescents. Lancet, 2016.MTA Cooperative Group. 14-month randomized clinical trial of treatment strategies for ADHD. Arch Gen Psychiatry, 1999, and follow-up reports.American Academy of Pediatrics. Clinical Practice Guideline for ADHD, 2019 (reaffirmed 2024). From Emora Health Emora Health, Adolescent psychiatryEmora Health, Editorial standards

---